Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...
Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...
Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>LDL</strong> (mg/dL)<br />
Define Trial: Effect of Anacetrapib on Plasma HDL and <strong>LDL</strong><br />
110<br />
100<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
Decrease <strong>LDL</strong> = 40%<br />
6 12 18 24 30 46 62 76<br />
Baseline Week<br />
Anacetrapib Placebo<br />
110<br />
100<br />
90<br />
80<br />
70<br />
60<br />
No. at Risk<br />
Anacetrapib 804 771756 716 687 646 604 568 540<br />
Placebo 803 759759 741 743 735 711 691 666<br />
HDL (mg/dL)<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
Increase HDL = 138%<br />
6 12 18 24 30 46 62 76<br />
Baseline Week<br />
No. at Risk<br />
Anacetrapib 807 776757 718 687 647 607 572 543<br />
Placebo 804 766761 741 744 736 711 691 666<br />
Cannon CP, et al. N Engl J Med. 2010;363(25):2406‐2415. Copyright © 2010 Massachusetts Medical Society.
Change language